单剂减毒活登革疫苗对菲律宾宿务儿童后续实验室确诊登革热风险的影响:一项纵向、前瞻性、人群队列研究
在菲律宾宿务,2017年入组9-14岁健康儿童,按基线登革病毒血清状态分层,评估单剂CYD-TDV对实验室确诊登革热的相对风险。单剂对基线无或仅一次感染儿童未显示保护;对基线两次及以上感染儿童,住院风险显著降低。
要点
- 单剂CYD-TDV对基线无或一次登革感染儿童未提供保护。
- 基线两次及以上感染儿童,单剂对住院保护67%(95%CI 19-87)。
- 作者认为结果不能用于公共卫生官员的接种决策。
核心结论
- 单剂CYD-TDV后实验室确诊登革热风险因基线登革病毒血清状态而异。
- 研究仅评估单剂效果,不能用于公共卫生官员的接种决策。
- 结果对接受不完整接种方案的儿童有启示,应促使未来疫苗试验更详细分析。
研究设计与样本
- 纵向、前瞻性、人群队列研究,2017年5月2日至6月2日在菲律宾宿务Bogo或Balamban入组9-14岁健康儿童。
- 通过Bogo农村卫生单位和Balamban三个农村卫生单位入组,收集人口学信息和基线登革病毒血清状态血清。
- 开展急性发热疾病主动监测,对出现急性发热疾病者收集临床数据并采血行RT-PCR确认登革热。
- 主要结局为按基线登革病毒血清状态分层的单剂CYD-TDV接种者与未接种者实验室确诊登革热的相对风险。
主要发现
- 单剂CYD-TDV对基线无或一次登革病毒感染的儿童未提供针对实验室确诊登革热的保护。
- 基线两次及以上登革病毒感染参与者中,单剂对实验室确诊登革热住院在前3年保护70%(95%CI 20-88;p=0.017)。
- 基线两次及以上登革病毒感染参与者中,单剂对实验室确诊登革热住院在整个随访期保护67%(95%CI 19-87;p=0.016)。
临床怎么用
- 作者认为研究仅评估单剂效果,不能用于公共卫生官员的接种决策。
- 作者认为结果对接受不完整接种方案的儿童有启示,应促使未来登革疫苗试验更详细分析。
局限性
- 研究仅评估单剂CYD-TDV的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A three-dose dengue vaccine (CYD-TDV) was licensed for use in children aged 9 years and older starting in 2015 in several dengue-endemic countries. In 2016, the Philippine Department of Health implemented a dengue vaccination programme, which was discontinued because of safety concerns. We assessed the relative risk of developing virologically confirmed dengue among children who did or did not receive a single dose of CYD-TDV by previous dengue virus (DENV) infections at baseline classified as none, one, and two or more infections. METHODS: In this longitudinal, prospective, population-based cohort study, we enrolled healthy children (aged 9-14 years) residing in Bogo or Balamban, Cebu, Philippines, between May 2, and June 2, 2017, before a mass dengue vaccination campaign, via the Rural Health Unit in Bogo and three Rural Health Units in Balamban. We collected demographic information and sera for baseline DENV serostatus and conducted active surveillance for acute febrile illness. Children who developed acute febrile illness were identified, clinical data were collected, and blood was drawn for confirmation of dengue by RT-PCR. The primary outcome was the relative risk of developing virologically confirmed dengue among children who received or did not receive a single dose of CYD-TDV by DENV serostatus at baseline. FINDINGS: A single dose of CYD-TDV did not confer protection against virologically confirmed dengue in children who had none or one previous DENV infection at baseline. One dose conferred significant protection against hospital admission for virologically confirmed dengue among participants who had two or more previous DENV infections at baseline during the first 3 years (70%, 95% CI 20-88; p=0·017) and the entire follow-up period (67%, 19-87; p=0·016). INTERPRETATION: The risk of developing virologically confirmed dengue after a single dose of CYD-TDV varied by baseline DENV serostatus. Since the study assessed the effect of only a single dose, the findings cannot inform decisions on vaccination by public health officers. However, the findings have implications for children who receive an incomplete vaccination regimen and these results should prompt more detailed analyses in future trials on dengue vaccines. FUNDING: The Philippine Department of Health, Hanako Foundation, WHO, Swedish International Development Cooperation Agency, International Vaccine Institute, University of North Carolina, and US National Institute of Allergy and Infectious Diseases.
引用
- Ylade M, Crisostomo MV, Daag JV, et al. Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study. Lancet Infect Dis. 2024. PMID: 38527474. doi:10.1016/S1473-3099(24)00099-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。